Israeli startup Virility Medical has raised $10 million for the skin patch it has developed to treat premature ejaculation.
The Virility Patch uses EMS (Electrical Muscle Stimulation) to prolong intercourse and enhance men’s natural physiological sexual performance. It improves their ability to contract the pelvic-floor muscles and postpone ejaculation.
The company, founded in 2016 and based in Hod Hasharon, says the patches should be available to buy from this Fall.
Migdal Insurance is investing $8 million in the startup and Arkin Holdings is putting in $2 million. Both investors are based in Israel.
In February 2021 Virility Medical announced an $8 million round of Series A investment, from Arkin and from Almeda Ventures.
“The Virility Patch creates a paradigm shift in sexual wellbeing, prolonging time until ejaculation and fulfilling the desire to last longer during sexual intercourse,” said founder Tal Gollan, who has a degree in biomedical engineering.
“The patch improves a man’s time to climax, creating a better outcome for couples. An estimated 79 million men suffer from premature ejaculation in the United States and in the EU, and more than 15 million men are actively looking for a medical solution to the problem.
“We’re bringing a ground-breaking, effective, and simple solution, with no side effects compared to existing products on the market.”
Premature ejaculation is the most common sexual dysfunction and is often treated with antidepressant drugs that have limited effects. They can also have side effects such as headaches and nausea, as well as diminished libido and decreased fertility.